ArticleFrontiers in oncology2024
The association between the interval from biopsy to radical prostatectomy and biochemical recurrence in patients with intermediate- and high-risk prostate cancer.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of Biopsy-to-Radical Prostatectomy Interval on Adverse Pathological Outcomes in High-Risk Localized and Locally Advanced Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Predicting the indication for adjuvant radiation therapy according to EAU guidelines among patients with high-risk prostate cancer: a novel multivariable model.Prostate cancer and prostatic diseases · 2026Article
- Article
- Personalized sports recommendation systems using robotic-assisted techniques in urologic oncology recovery.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the association between the interval from biopsy to radical prostatectomy (RP) and biochemical recurrence (BCR) in prostate cancer patients. Methods: Within a tertiary-care database (01/2014 to 06/2023), D'Amico intermediate- and high-risk prostate cancer patients were stratified according to interval from biopsy to RP (≤3 vs. >3-≤6 months). Kaplan-Meier survival analyses and Cox regression models addressed BCR. Results: Of 680 patients, 328 vs. 153 exhibited intermediate-risk prostate cancer and had interval from biopsy to RP ≤3 vs. >3-≤6 months. Similarly, 158 vs. 41 exhibited high-risk prostate cancer and had interval from biopsy to RP ≤3 vs. >3-≤6 months. Median interval from biopsy to RP was 59 vs. 113 days in intermediate- and 55 vs. 117 days in high-risk patients, respectively. In both intermediate- and high-risk patients, rates of adverse histopathological outcomes, namely pT3/pT4, pN1, and R1 status, did not differ according to interval from biopsy to RP. In survival analyses, three-year BCR-free survival rates were 82 vs. 88% in intermediate-risk (p=0.5) and 76 vs. 75% in high-risk patients (p=1). In multivariable Cox regression models, BCR did not significantly differ according to interval from biopsy to RP in intermediate- (hazard ratio 0.85, 95% confidence interval 0.49-1.46; p=0.5) and high-risk patients (hazard ratio 1.05, 95% confidence interval 0.50-2.22; p=0.9). Conclusions: Both intermediate- and high-risk prostate cancer patients with an interval from biopsy to RP >3-≤6 months did not differ from those treated with RP ≤3 months after biopsy, regarding adverse histopathological outcomes and BCR rates. Therefore, it might be safe to postpone RP up to six months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.